The Quantellect read.As of Nov 19, 2026, 3 active firms cover Tenaya Therapeutics Inc: 3 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $3.00 to $8.00 (about 2.7x), a sign of real disagreement on valuation. The average target of $5.33 sits 1671% above the current $0.30. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.08 next quarter toward $-0.36 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Buy
Strong Buy00%
Buy3100%
Neutral00%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$5.33
+1670.7% upside
Average target across 3 active firms as of Nov 19, 2026 vs $0.30 current
Highest Target$8.00
Average Target$5.33
Lowest Target$3.00
Detailed analyst forecasts for TNYA
Showing 1–3 of 3 named analysts shown · 3 active firms in the rating projection
As of Nov 19, 2026, 3 of 3 active firms rate TNYA a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
TNYA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.08
Range $-0.09 – $-0.07 · 3 analysts · -7% YoY
Next period, 3 analysts expect Tenaya Therapeutics Inc to earn $-0.08 a share (range $-0.09 – $-0.07), versus $-0.09 a year earlier. Full-year consensus is $-0.44, growing to $-0.36 the year after.
REVENUE · NEXT QUARTER
$550.0K
Range $0 – $1.1M · 3 analysts · +144% YoY
Revenue is expected to reach $550.0K (range $0 – $1.1M), +144.4% year-over-year. Full-year consensus is $3.8M, rising to $4.1M next year.
Top analysts covering Tenaya Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TNYA.
#1
Geulah Livshits
Chardan Capital · Rank #104
Buy
$8.00+2556.0% to target
Overall win rate
43%
+ Follow
#2
Yasmeen Rahimi
Piper Sandler · Rank #339
Buy
$40.00+13180.2% to target
Overall win rate
30%
+ Follow
#3
Joseph Pantginis
HC Wainwright & Co. · Rank #373
Buy
$3.00+896.0% to target
Overall win rate
34%
+ Follow
#4
WI
Whitney Ijem
Canaccord Genuity · Rank #392
Buy
$5.00+1560.0% to target
Overall win rate
35%
+ Follow
#5
Matthew Harrison
Morgan Stanley · Rank #393
Buy
$5.00+1560.0% to target
Overall win rate
44%
+ Follow
TNYA stock forecast FAQ
What is TNYA's average 12-month price target?+
The 3 active firms with a live target average $5.33 for Tenaya Therapeutics Inc over the next 12 months, ranging from a $8.00 high to a $3.00 low, as of Nov 19, 2026.
Is TNYA stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 3 active firms as of Nov 19, 2026, 3 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for TNYA?+
The Street-high target is $8.00 (Chardan Capital), and the Street-low is $3.00 (HC Wainwright & Co.). The average of all 3 active-firm targets is $5.33.
How many active Wall Street firms cover TNYA?+
3 active firms have a recognized rating on Tenaya Therapeutics Inc as of Nov 19, 2026, and 3 active firms carry a live 12-month price target.
Who is the most accurate analyst covering TNYA?+
Among analysts who currently cover TNYA, Geulah Livshits of Chardan Capital has the strongest overall Quantellect track record (Rank #104). Their current call is Buy with a $8.00 target.
What is Tenaya Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.08 per share (range $-0.09 – $-0.07) across 3 analysts. Full-year EPS is projected at $-0.44, rising to $-0.36 the following year.
How much revenue is Tenaya Therapeutics Inc expected to report next quarter?+
Consensus revenue is $550.0K (range $0 – $1.1M). Full-year revenue is projected at $3.8M, growing to $4.1M next year.
Have analysts been upgrading or downgrading TNYA lately?+
As of Nov 19, 2026, 3 of 3 active firms rate TNYA a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TNYA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.